CT 100

Drug Profile

CT 100

Alternative Names: CT100

Latest Information Update: 27 Jan 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Celleron Therapeutics
  • Class Antineoplastics; Flavonoids
  • Mechanism of Action Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 27 Jan 2011 This programme is in active development
  • 14 Nov 2007 CT 100 is available for licensing (http://cellerontherapeutics.com)
  • 14 Nov 2007 Phase-I clinical trials in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top